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the concomitant administration of ganciclovir in 2 patients.
The median serum creatinine (SCr) (mg/dl, range) prior to,
during, and post-FOS CI were 1.3 (0.7-2.2), 1.15 (0.7-2.0), and
1.9 (0.9-7.1), respectively. In the analysis of individual data,
median net change in SCr was 0.3 mg/dl (range: -0.9 to +5.7)
from the pre- to the post-FOS period, although one patient
developed renal failure shortly before dying of multi-organ
failure, GVHD and persistent CMV disease.
Conclusion: FOS CI permitted the safe administration of
outpatient treatment in patients at high risk for nephrotox-
icity with CMV reactivation and/or disease which, in our
experience, has increased the utility of this drug. Data
regarding comparative efﬁcacy to standard infusion will
require additional study.285
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Background: Romiplostim is a thrombopoietin receptor
agonist utilized in the treatment of pediatric patients with
immune thrombocytopenia. Furthermore, the limited
toxicity of romiplostim makes this an attractive option for
the treatment of post-HSCT immune thrombocytopenia. We
describe a 3-year-old male with X-linked chronic granulo-
matous disease (CGD) treated with unrelated donor HSCT.
His course was complicated by immune dysregulation
manifest as recurrent pleural effusions that improved with
corticosteroids. At 1-year post HSCT, after stopping his cor-
ticosteroids he developed symptomatic thrombocytopenia
and autoimmune hemolytic anemia (AIHA). He was started
on romiplostimwith improvement in his thrombocytopenia.
Methods: A 3-year-old Asian male was diagnosed with
X-CGD. The patient underwent HSCT utilizing a 9/10 HLA
matched unrelated female donor. The preparative regimen
was: busulfan (0.8 mg/kg/dose x 16 doses), cytoxan (50 mg/
kg/dose x 4 doses), ﬂudarabine (30mg/m2) and Campath
(2 mg x 4 doses). Graft-versus-host disease prophylaxis was:
cyclosporine and methotrexate. Post-HSCT he developed
seizures and mucositis. He engrafted on Day +18 with 100%
donor engraftment. On Day +62 and +119 he presented with
symptomatic pleural effusions. Evaluation for infectious
pathogens was negative. On both occasions a response to
corticosteroids was documented. At 1-year post-HSCT as his
corticosteroid taper ﬁnished he developed symptomatic
thrombocytopenia (platelet count 5,000 / uL).
Results: He was treated with intravenous immunoglobulin
and platelet transfusion without signiﬁcant improvement. In
addition to symptomatic thrombocytopenia a warm AIHA
(hemoglobin 5.2 g / dL) emerged. Evaluation for infectious
pathogens was negative. A bone marrow examination
demonstrated a cellular marrow with trilineage hemato-
poiesis, megakaryocytic hypoplasia, and erythroid hyper-
plasia. Cytogenetic evaluation demonstrated a normal male
karyotype and chimerism studies documented 98% donor
engraftment. In order to avoid the toxicity associated with
corticosteroid use romiplostim was started at 5 mcg/kg
subcutaneous each week. Within three 3 weeks of starting
therapy his platelet count was> 50,000 / uL. He continues to
maintain a platelet count > 100,000 / uL while tapering hisromiplostim dose. His hemoglobin also continued to improve
without a need for transfusion support.
Conclusion: To our knowledge, this is the ﬁrst description of a
successful application of romiplostim as initial therapy in a
pediatric patient with immune thrombocytopenia following
matched unrelated donor HSCT for X-linked CGD. We found
that the use of romiplostim to be an effective and safe alter-
native to thepotentialmorbidityandmortality associatedwith
the use of immunosuppressive agents such as corticosteroids.286
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Hematopoietic progenitor stem cell transplantation (HSCT)
has different stages; the presence of anxiety and psycho-
logical disorders is frequently reported. Objective. To assess
and compare the patient’s psychological state before and
after HSCT, evaluating the level of anxiety, emotional in-
dicators and external variables which inﬂuence the psycho-
logical state. Method. First stage, pre- HSCT, 70 patients were
assessed: 26 females and 44 males, from the Oncological,
Hematological and Immunological departments. Age: 6-18
years old, appropriate for tests. Registration: age, gender,
diagnosis, date of diagnosis, hospital stay and family dy-
namics. Standardized psychological tests and semi-struc-
tured interview. Second stage, post- HSCT. Same assessment
but with 18 patients. Results. 70% of patients showed social
concerns. With regards to their family, most of them had at
least 2 emotional indicators. Most patients with high pre-
HSCT decreased their anxiety levels during the post- HSCT,
while most of the ones with low anxiety remained the same.
Conclusions. Psychological assessment and preparation in-
creases the possibility of knowing variables that inﬂuence
the patient’s emotional status and create a treatment plan
appropriate for him/her.287
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Background: Since the inception of the pediatric transplant
program at the University of Mississippi Medical Center
(UMMC), intravenous gammaglobulin (IVIG) has been given
biweekly prophylactically post- transplant for up to 100 days
post transplantation. Many authors now report a lack of ef-
ﬁcacy in administering IVIG for this purpose and perhaps
adverse events such as infection, reaction, and even a higher
risk of veno-occlusive disease.
Methods: As a performance improvement project, a retro-
spective chart audit was completed to measure actual levels
of immunoglobulin G (IgG) in our transplant patients to see if
low levels of immunoglobulin G (IGG) could be identiﬁed.
Patients were characterized by age (at time of transplant),
Figure 1. Perception of Likelihood of cure with HSCT (P < 0.0001)
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the normal range and the IgG levels in the low range were
compared and analyzed based on type of transplant, disease,
age (at transplant), and gender.
Results: 76 charts were reviewed. 10 charts had no post-
transplant levels ever documented. 53 had normal IgG levels,
and 13 had low IgG levels post-transplant. Characteristics
common to the majority of patients with low IgG included
allogeneic transplantation and leukemia or lymphoma as a
diagnosis.
Conclusions: IVIG replacement is not indicated based on
levels of IgG in patients undergoing autologous stem cell
transplantation or who have an underlying diagnosis other
than leukemia or lymphoma.288
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Introduction: During hematopoietic stem cell trans-
plantation (HSCT), patients receive high dose chemotherapyTable 1
Longitudinal QOL and Mood by type of HSCT
Outcomes Type
HSCT
Week-1 Week-2 Week-3 P-Value
QOL, M Auto
Allo
105.8
101.1
95.4
97.6
93.7
96.3
P ¼ 0.0003
P[ 0.01
Fatigue, M Auto
Allo
34.4
39.0
27.0
34.9
27.3
29.7
P < 0.0001
P[ 0.01
HADS depression
> 7, N (%)
Auto
Allo
7 (23%)
3 (13%)
11 (37%)
6 (26%)
13 (43%)
6 (26%)
P ¼ 0.0003
P[ 0.05during a prolonged hospitalization and endure signiﬁcant
side effects in the hopes of curing their disease. While many
studies have focused on the long-term outcomes of patients
undergoing HSCT, the acute impact of hospitalization for
HSCT on patients’ quality of life (QOL), symptom burden, and
mood is unknown. Furthermore, data on patients’ perception
of their prognosis and likelihood of cure with HSCT are
lacking.
Methods: We conducted a prospective longitudinal study of
patients hospitalized at the Massachusetts General Hospital
for HSCT. At baseline and weeks 1, 2, and 3 of hospitalization,
we assessed QOL (Functional Assessment of Cancer Therapy-
Bone Marrow Transplantation [FACT-BMT]; higher scores
indicate better QOL), fatigue (FACT-Fatigue; higher scores
indicate less fatigue), and mood (Hospital Anxiety and
Depression Scale score> 7 on anxiety or depression subscale
considered clinically signiﬁcant). Using a 10-item question-
naire, we measured patients’ information preferences, and
perception of their prognosis.
Results: We enrolled 53 consecutive patients undergoing
autologous (n¼30), ormyeloablative allogeneic (n¼23) HSCT.
Patients’ QOL declined (FACT BMT mean scores week 1:107.5
àweek 2: 96.3 àweek 3: 94.8, p < 0.0001), and fatigue
increased (FACT Fatigue mean scores week1: 36.4 à week 2:
30.5 à week 3: 28.3, p < 0.0001) throughout hospitalization.
The proportion of patients with depression symptoms
increased from baseline to week 3 (18.9% to 35.8%; p¼0.002)
whereas the proportion of patients with anxiety symptoms
did not change signiﬁcantly from baseline (22.6%; p¼0.7).
These patterns remained consistent when data were strati-
ﬁed by the type of HSCT [Table 1]. Although 90.6% (48/53) of
patients stated that it is ‘extremely’ or ‘very’ important to
know about their prognosis, 76.0% (38/50) reported inaccu-
rate and overly optimistic perception of their prognosis
compared to their physicians (p < 0.0001) [Figure 1].
Conclusion: Patients with hematologic malignancies un-
dergoing HSCT report an overly optimistic perception of their
prognosis and experience signiﬁcant decline in QOL with
increasing symptom burden and rates of depression
throughout their hospitalization. Results suggest that in-
terventions to both improve the QOL and psychological
outcomes of patients hospitalized for HSCT and enhance
their prognostic awareness are clearly warranted.289
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